Mamta Kalra, PhD, is Vice President of Process and Analytical Development at Immatics, with over 15 years of experience in cell and gene therapy. Since joining Immatics in 2016, she has helped advance ACTengine® and next-generation TCR-T programs. Her expertise spans process and analytical development, viral vectors, potency strategies, comparability, validation and regulatory CMC. She leads teams advancing T-cell therapies from early clinical development through late-stage development and commercial readiness, connecting scientific innovation with robust, scalable and cost-efficient manufacturing. Mamta holds a PhD in Immunology from the Postgraduate Institute of Medical Education and Research, India, and completed postdoctoral training in adoptive T-cell therapy at Baylor College of Medicine.